- World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
- First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
- QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
- Appointment of Dr Darren Patti to Group Chief Operating Officer
- Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
- Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
More ▼
Key statistics
On Thursday, Telix Pharmaceuticals Ltd (TLX:ASX) closed at 12.89, -4.80% below its 52-week high of 13.54, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.91 |
---|---|
High | 13.00 |
Low | 12.80 |
Bid | 12.86 |
Offer | 12.97 |
Previous close | 12.86 |
Average volume | 1.85m |
---|---|
Shares outstanding | 323.99m |
Free float | 241.31m |
P/E (TTM) | 910.12 |
Market cap | 4.17bn AUD |
EPS (TTM) | 0.0141 AUD |
Data delayed at least 20 minutes, as of Mar 28 2024 05:10 BST.
More ▼